<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="83788">
  <stage>Registered</stage>
  <submitdate>5/04/2009</submitdate>
  <approvaldate>28/05/2009</approvaldate>
  <actrnumber>ACTRN12609000380291</actrnumber>
  <trial_identification>
    <studytitle>Assessing in young Australian adults whether exposure to simulated solar ultraviolet radiation affects immune response to primary vaccination.</studytitle>
    <scientifictitle>Assessing in healthy young Australian fair-skinned adults whether exposure to simulated solar ultraviolet radiation (UVR) affects immune response to primary vaccination.</scientifictitle>
    <utrn />
    <trialacronym>AusUVI</trialacronym>
  </trial_identification>
  <conditions>
    <healthcondition>Impact of solar ultraviolet radiation on human primary immune response to immunisation with a T-dependent antigen (Keyhole Limpet Haemocyanin)</healthcondition>
    <conditioncode>
      <conditioncode1>Inflammatory and Immune System</conditioncode1>
      <conditioncode2>Normal development and function of the immune system</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>The intervention group will receive 0.8 x minimal erythemal dose of simulated solar UVR daily for five days  (via a calibrated UVR lamp) delivered to a 5x5cm area of skin over the lower thigh.  On the day following the last dose of UVR, participants will be vaccinated with 125mcg of Keyhole Limpet Haemocyanin (KLH) with Montanide-ISA 51 adjuvant subcutaneously to the site of irradiation.</interventions>
    <comparator>The control group will undertake sun protection measures for 5 days.  This involves use of broad spectrum sun screen and protective clothing when outside.  On the day following the last day of UVR avoidance, participants will be vaccinated with 125mcg of Keyhole Limpet Haemocyanin (KLH) with Montanide-ISA 51 adjuvant subcutaneously to the lower thigh.</comparator>
    <control>Active</control>
    <interventioncode>Other interventions</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Humoral response to primary subcutaneous vaccination with Keyhole Limpet Haemocyanin (KLH).  KLH-specific immunoglobulins (Ig)  (Ig types M, E, G and subsets) will be quantified via enzyme linked immunoassay techniques.</outcome>
      <timepoint>KLH specific antibody titres taken at baseline (immediately prior to vaccination which follows the 5 days of UVR irradiation or sun avoidance); 1 week and 3 weeks post vaccination</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Delayed-type hypersensitivity (DTH) response to intra-dermal KLH will be measured in millimetres of skin reaction.</outcome>
      <timepoint>Intradermal KLH given at day 21 post vaccination.  DTH response read at 48 hours post intradermal KLH.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>KLH specific T-cell response will be measured via lymphocyte proliferation assays.</outcome>
      <timepoint>Measured at baseline (immediately prior to vaccination) and day 21.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>* Age 18 - 40 years
* Fitzpatrick Type II-III skin (fair skin which sunburns without difficulty)
* Willing and able to sign informed consent</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>40</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>* Allergy to shellfish
* Pregnancy or breastfeeding
* Previous KLH vaccination
* Immunosuppressive medications
* Immunosuppressive medical condition
* Recent infection (within 2 weeks of vaccination)
* Recent immunisation with any other vaccine in past 4 weeks
* Photosensitive skin or taking photosensitsing medication</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Prevention</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Allocation will occur via computer generated randomisation.  Allocation is not concealed.</concealment>
    <sequence>Simple randomisation by using a randomization table created by computer software</sequence>
    <masking>Open (masking not used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate>11/05/2009</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>30</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Individual</primarysponsortype>
    <primarysponsorname>Dr Ashwin Swaminathan</primarysponsorname>
    <primarysponsoraddress>National Centre for Epidemiology and Population Health,
Building 62
Australian National University
Canberra 
Australian Capital Territory 0200</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Self funded/Unfunded</fundingtype>
      <fundingname />
      <fundingaddress />
      <fundingcountry />
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
    <othercollaborator>
      <othercollaboratortype>Individual</othercollaboratortype>
      <othercollaboratorname>Dr Robyn Lucas</othercollaboratorname>
      <othercollaboratoraddress>National Centre for Epidemiology and Population Health,
Building 62
Australian National University
Canberra 
Australian Capital Territory 0200</othercollaboratoraddress>
      <othercollaboratorcountry>Australia</othercollaboratorcountry>
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Individual</othercollaboratortype>
      <othercollaboratorname>Assoc/Prof Michael Kimlin</othercollaboratorname>
      <othercollaboratoraddress>Australian Sun and Health Research Laboratory 
O Block, D wing
Victoria Park Road,
Kelvin Grove QLD, 4059, Australia 
Queensland University of Technology</othercollaboratoraddress>
      <othercollaboratorcountry>Australia</othercollaboratorcountry>
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Individual</othercollaboratortype>
      <othercollaboratorname>Professor Tony McMichael</othercollaboratorname>
      <othercollaboratoraddress>National Centre for Epidemiology and Population Health,
Building 62
Australian National University
Canberra Australian Capital Territory 0200</othercollaboratoraddress>
      <othercollaboratorcountry>Australia</othercollaboratorcountry>
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Individual</othercollaboratortype>
      <othercollaboratorname>Dr Matthew Cook</othercollaboratorname>
      <othercollaboratoraddress>Immunology Department
Canberra Hospital
Yamba Drive
Garran Canberra
Australian Capital Territory 2605</othercollaboratoraddress>
      <othercollaboratorcountry>Australia</othercollaboratorcountry>
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>This study aims to determine whether exposure to simulated solar ultraviolet radiation at levels relevant to normal daily activities can suppress the immune response to vaccination.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Human Research Ethics Committee, Australian National University</ethicname>
      <ethicaddress>Office of Research Integrity
Research Office
Chancelry Building 10B
The Australian National University
Canberra, ACT  0200</ethicaddress>
      <ethicapprovaldate>3/04/2009</ethicapprovaldate>
      <hrec>2009/031</hrec>
      <ethicsubmitdate>11/03/2009</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Ashwin Swaminathan</name>
      <address>National Centre for Epidemiology and Population Health
Building 62 
Australian National University
Canberra 
Australian Capital Territory 0200</address>
      <phone>+61 (0)2 6125 2378</phone>
      <fax />
      <email>ashwin.swaminathan@anu.edu.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Ashwin Swaminathan</name>
      <address>National Centre for Epidemiology and Population Health
Building 62 
Australian National University
Canberra 
Australian Capital Territory 0200</address>
      <phone>+61 (0)2 6125 2378</phone>
      <fax />
      <email>ashwin.swaminathan@anu.edu.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Ashwin Swaminathan</name>
      <address>National Centre for Epidemiology and Population Health
Building 62 
Australian National University
Canberra 
Australian Capital Territory 
0200</address>
      <phone>+61 (0)2 6125 2378</phone>
      <fax />
      <email>ashwin.swaminathan@anu.edu.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>